rais estim pt
management continu execut well companion anim
momentum remain strong tweak model
rais revenue est ep est
rais pt maintain equal weight
increas ep estim rais revenu
estim bump ep estim follow
vs guidanc rang
estim revis figur vs consensu
rais pt increas pt old
ep new ep new valuat multipl
high end histor rang current next month
multipl see exhibit assign higher valuat due
solid execut stellar/consist track record beaten con ep
european recommend approv key pipelin product simparica trio
tripl oral combo flea/tick/heartworm coverag higher project
growth rais compound-annual-growth-rate revenue ep
fuel growth stori apoquel cytopoint simparica continu
import growth driver zoeti addit zoeti expect launch new
product simparica trio flea tick heartworm monoclon
antibodi mab pain cat eu us strateg zoeti
view cat market under-tr zoeti also progress mab pain
dog could file near-medium term regard simparica trio
largest opportun lie within us market flea/tick/heartworm
heartworm preval trio expect first tripl
combo market global treatment flea/tick/heartworm repres
market flee tick heartworm us ex-u
intern heartworm preval australia japan ex-eu
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
base case ep target multipl high
end histor rang given strong pipelin prospect project
bull case ep
bull case ep
new product upsid drive faster revenu growth project zoeti
pursu value-enhanc organ ep upsid plu upsid
yield ep forecast tuck-in could enhanc
base case ep
base case ep
project low double-digit ep growth driven growth key companion
anim product project compound-annual-growth-rate revenu growth ep compound-annual-growth-rate
larger intern market share growth beyond
global roll-out new product give us confid project
bear case ep
bear case ep
fda delay approv simparica trio face lower end-market growth
approv simparica trio zoeti face new competitor key
companion anim franchis compani miss ep estimate price-to-earnings
zoeti combin compel
ep growth
posit new product develop
revenu perform margin
livestock rev demand
meat milk project least doubl
next year due larg part
popul growth increas
affluenc emerg market
companion anim rev
global spend pet grow
quarterli result guidanc updat
new product ramp rel
zoeti becom activ deploy
capit acquir products/compani
competitor perform better/wors
competitor could launch product
compet directli key zoeti growth
risk achiev price
new product approv delay
margin expans fail materi
new govern regul legisl
impact growth
dollar strength rel foreign
despit pressur african swine fever asf livestock sale return growth
larg driven poultri total revenue product grew
oper asf contribut china livestock oper declin note
zoeti china revenu includ swine estim total
full year swine revenu impact impact littl
howev neg impact asf off-set strong perform
elsewher zoeti experienc strong china companion anim growth management also
state region primarili brazil eu expect increas pork export
china time magnitud remain uncertain take time invest
infrastructur increas product
exhibit consensu ntm price-to-earnings vs spec pharma average continu trade larg
premium group
exhibit incom statement margin valuat
sg op exp
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
